Abionyx PharmaLTS:0RAG +1.45%29 PB Ratio is 16.71 as of Jul. 02, 2026, which is 236% above its 10-year median of 4.97. GuruFocus rates LTS:0RAG with a GF Score™ of 29/100 and a GF Value™ of €0.85 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Abionyx Pharma ranks worse than 91.61% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-02), Abionyx Pharma's share price is €2.105. Abionyx Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was €0.13. Hence, Abionyx Pharma's PB Ratio of today is 16.71.
The historical rank and industry rank for Abionyx Pharma's PB Ratio or its related term are showing as below:
LTS:0RAG'
s PB Ratio Range Over the Past 10 Years
Min: 1.01 Med: 4.97 Max: 31.89
Current: 16.95
During the past 13 years, Abionyx Pharma's highest PB Ratio was 31.89. The lowest was 1.01. And the median was 4.97.
LTS:0RAG's PB Ratio is ranked worse than 91.61% of 1228
companies
in the Biotechnology industry
Industry Median: 2.95
vs LTS:0RAG: 16.95
During the past 12 months, Abionyx Pharma's average Book Value Per Share Growth Rate was -41.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -20.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -14.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -16.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Abionyx Pharma was 683.00% per year. The lowest was -52.20% per year. And the median was -11.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Abionyx Pharma PB Ratio Related Terms
Abionyx Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Abionyx Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Abionyx Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abionyx Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abionyx Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Abionyx Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Abionyx Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Abionyx Pharma (LTS:0RAG) has a PB Ratio of 16.71 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Abionyx Pharma and its competitors. This is 236% above median its historical median of 4.97. Over the past decade, Abionyx Pharma's PB Ratio has ranged from 1.01 to 31.89. According to the industry distribution chart, Abionyx Pharma ranks #1125 out of 1228 companies in the Biotechnology industry, placing it in the top 91.6%.
Is Abionyx Pharma's PB Ratio too high?
Abionyx Pharma's current PB Ratio of 16.71 is 236% above median its 10-year median of 4.97. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 31.89. The Biotechnology industry median PB Ratio is 2.95. Abionyx Pharma's value of 16.71 is 466.4% above this industry median. Based on the distribution chart, Abionyx Pharma ranks #1125 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abionyx Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abionyx Pharma ranks #1125 out of 1228 companies for PB Ratio. This places Abionyx Pharma in the lower half of its industry. The industry median PB Ratio is 2.95. Abionyx Pharma's value of 16.71 is 466.4% above this benchmark. Historically, Abionyx Pharma's own PB Ratio has ranged from 1.01 to 31.89 over the past decade. While the company's 10-year median is 4.97 vs. the industry median of 2.95, Abionyx Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abionyx Pharma's current PB Ratio of 16.71 is 466.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Abionyx Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abionyx Pharma's current PB Ratio is 16.71, which is 236% above median its own 10-year median of 4.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (LTS:0RAG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.85, compared to a current price of €2.11 — trading 147.6% above its estimated fair value. The current PB Ratio is 16.71, which is 236% above median its 10-year median of 4.97 and 466.4% above the Biotechnology industry median of 2.95. Abionyx Pharma's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Abionyx Pharma (LTS:0RAG), the current PB Ratio is 16.71 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abionyx Pharma (LTS:0RAG) Overvalued in 2026?
Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued.
The current stock price of €2.11 is trading 147.6% above its estimated GF Value™ of €0.85.
GuruFocus considers Abionyx Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0RAG:
PB Ratio: 16.71 (236% above median its 10-year median of 4.97)
GF Value™: €0.85 vs. price of €2.11 (147.6% above fair value)
Industry Position: 466.4% above the Biotechnology median (#1125 of 1228)
No single metric tells the full story. See the LTS:0RAG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
29GF Score
Get the complete analysis for LTS:0RAG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAG has been successfully added to your 
